TP53 and non-small cell lung carcinoma: Although the prognostic or predictive value of TP53 mutations has been inconclusive in NSCLC cases [17–23], recent studies demonstrated that antiangiogenic-based therapy may be appropriate for the treatment of TP53-mutant NSCLC [24–26].